| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Novo Nordisk A/S | Semaglutide - (STEP HFpEF) | Heart failure with preserved ejection fraction (HFpEF) and obesity, Type 2 diabetes | NDA Filing | Trial Completed | Subcutaneous | Cardiology |
| Novo Nordisk A/S | Insulin icodec - (ONWARDS-5) | Type 2 diabetes | NDA Filing | Trial Completed | Subcutaneous | Endocrinology |
| Novo Nordisk A/S | Zaltenibart - (OMS906) | Paroxysmal nocturnal hemoglobinuria (PNH) | Phase 3 | Enrollment Initiation | Intravenous | Hematology |
| Novo Nordisk A/S | Zaltenibart - (OMS906) | Paroxysmal nocturnal hemoglobinuria (PNH) | Phase 3 | Enrollment Initiation | Intravenous | Hematology |
| Novo Nordisk A/S | Insulin icodec - (ONWARDS-1) | Type 2 diabetes | Phase 3 | Data Released | Subcutaneous | Endocrinology |
| Novo Nordisk A/S | Coramitug (PRX004) - (CLEOPATTRA) | ATTR-cardiomyopathy | Phase 3 | Ongoing | intravenous | Cardiology |
| Novo Nordisk A/S | Insulin icodec - (ONWARDS-1) | Type 2 diabetes | Phase 3 | Data Released | Subcutaneous | Endocrinology |
| Novo Nordisk A/S | Mim8 - (FRONTIER2) | Hemophilia A | Phase 3 | Trial Completed | Subcutaneous | Hematology |